Atlas Trials

A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma

Clinical trial NCT02234986 · COMPLETED

Trial details

NCT number
NCT02234986
Sponsor
CASI pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced Adult Hepatocellular CarcinomaAdvanced Fibrolamellar Carcinoma
Start date
2015-10-01
Primary completion
2018-06-30
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.